Product Overview

Development Status: Limited Market Approval

Target: Female

Mode: Hormonal

Delivery Type: Injectable

Duration Type: Short-acting

Description: Combined monthly injectable.

Updated date: May 30, 2018

Vertical Tabs


Project Phase: Post-development

Project Stage: Marketed

Status Details:
  • CycloFem is registered and in use in Indonesia and a few countries in Latin America. Concept Foundation has the commercial rights. CONRAD has conducted PK studies on CycloFem to support the US FDA approval process.
  • The same formulation was previously approved in the US as Lunelle (in 2000), marketed by Pfizer, but was removed from the market because of production problems.

Download Product Report